Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 4, 2011, Pages 829-835

  Ueda, Yutaka ^a   Miyake, Takahito ^b   Egawa Takata, Tomomi ^a   Miyatake, Takashi ^a   Matsuzaki, Shinya ^a   Yokoyama, Takuhei ^a   Yoshino, Kiyoshi ^a   Fujita, Masami ^a   Enomoto, Takayuki ^a   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Endometrial cancer; Overall survival; Progression free survival; Response; Second line chemotherapy; Treatment free interval

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; IRINOTECAN; MEDROXYPROGESTERONE ACETATE; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SECOND LINE CHEMOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954427920     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1384-z     Document Type: Article

References (24)

1. DiSaia PJ, Creasman WT (2002) Clinical gynecologic oncology, 6th edn. St. Louis, Mosby
2. RE Bristow MJ Zerbe NB Rosenshein FC Grumbine FJ Montz 2000 Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival Gynecol Oncol 78 85 91 10926785 10.1006/gyno.2000.5843 1:STN:280:DC%2BD3cvht1eksA%3D%3D (Pubitemid 30650336)
3. Berek JS (2002) Novak's Gynecology, 13th edn. William and Wilkins, Baltimore
4. ME Randall VL Filiaci H Muss NM Spirtos RS Mannel J Fowler JT Thigpen JA Benda 2006 Gynecologic oncology group study randomized phase iii trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study J Clin Oncol 24 36 44 16330675 10.1200/JCO.2004.00.7617 1:CAS:528:DC%2BD28Xot1Chug%3D%3D (Pubitemid 46630491)
5. N Susumu S Sagae Y Udagawa K Niwa H Kuramoto S Satoh R Kudo 2008 Japanese gynecologic oncology group randomized phase iii trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high risk endometrial cancer: a Japanese gynecologic oncology group study Gynecol Oncol 108 226 233 17996926 10.1016/j.ygyno.2007.09.029 1:CAS:528:DC%2BD1cXhtlShsw%3D%3D (Pubitemid 350299451)
6. MS Aapro FH van Wijk G Bolis B Chevallier ME van der Burg A Poveda CF de Oliveira S Tumolo V Scotto di Palumbo M Piccart M Franchi F Zanaboni AJ Lacave R Fontanelli G Favalli P Zola JP Guastalla R Rosso C Marth M Nooij M Presti C Scarabelli TA Splinter E Ploch LV Beex W Ten Bokkel Huinink M Forni M Melpignano P Blake P Kerbrat C Mendiola A Cervantes A Goupil PG Harper C Madronal M Namer G Scarfone JE Stoot I Teodorovic C Coens I Vergote JB Vermorken 2003 European organisation for research, treatment of cancer gynaecological cancer group. Doxorubicin versus doxorubicin, cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC gynaecological cancer group Ann Oncol 14 441 448 12598351 10.1093/annonc/mdg112 1:STN:280: DC%2BD3s%2Fos1Glsg%3D%3D (Pubitemid 36367423)
7. HG Ball JA Blessing SS Lentz DG Mutch 1996 A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a gynecologic oncology group study Gynecol Oncol 62 278 281 8751561 10.1006/gyno.1996.0227 1:CAS:528:DyaK28Xls1Grtrs%3D (Pubitemid 26274811)
8. GF Fleming VL Brunetto D Cella KY Look GC Reid AR Munkarah R Kline RA Burger A Goodman RT Burks 2004 Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 22 2159 2166 15169803 10.1200/JCO.2004.07.184 1:CAS:528:DC%2BD2cXpsVWltrw%3D (Pubitemid 41095150)
9. A Lissoni A Gabriele G Gorga S Tumolo F Landoni C Mangioni C Sessa 1997 Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma Ann Oncol 8 969 972 9402169 10.1023/A:1008221310453 1:STN:280:DyaK1c%2FmtlOlsw%3D%3D (Pubitemid 27475727)
10. MA Sovak ML Hensley J Dupont N Ishill KM Alektiar N Abu-Rustum R Barakat DS Chi P Sabbatini DR Spriggs C Aghajanian 2006 Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study Gynecol Oncol 103 451 457 16677690 10.1016/j.ygyno.2006.03.019 1:CAS:528:DC%2BD28XhtFegtbbL (Pubitemid 44740097)
11. CA Papadimitriou D Bafaloukos G Bozas H Kalofonos P Kosmidis G Aravantinos G Fountzilas MA Dimopoulos 2008 Hellenic co-operative oncology group. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic co-operative oncology group (HeCOG) study Gynecol Oncol 110 87 92 18455782 10.1016/j.ygyno.2008.03.004 1:CAS:528:DC%2BD1cXnvVOksrk%3D
12. PJ Hoskins KD Swenerton JA Pike F Wong P Lim C Acquino-Parsons N Lee 2001 Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study J Clin Oncol 19 4048 4053 11600606 1:CAS:528:DC%2BD3MXotVakt7w%3D (Pubitemid 32976691)
13. A du Bois JP Neijt JT Thigpen 1999 First-line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care? Ann Oncol 10 Suppl 1 35 41 10219451 10.1023/A:1008355317514
14. LJ Havrilesky AA Alvarez RA Sayer JM Lancaster JT Soper A Berchuck DL Clarke-Pearson GC Rodriguez ME Carney 2003 Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer Gynecol Oncol 88 51 57 12504627 10.1006/gyno.2002.6859 1:CAS:528:DC%2BD38Xps12rsrg%3D (Pubitemid 36062665)
15. A Kikuchi H Sakamoto T Yamamoto 2005 Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy Int J Gynecol Cancer 15 45 49 15670296 10.1111/j.1048-891X.2005.15006.x 1:STN:280:DC%2BD2M%2FktlGgsQ%3D%3D (Pubitemid 40194332)
16. World Health Organization (1979) WHO handbook of reporting results of cancer treatment no. 48. WHO Offset Publication, Geneva
17. D Pectasides N Xiros G Papaxoinis E Pectasides C Sykiotis A Koumarianou A Psyrri A Gaglia D Kassanos P Gouveris J Panayiotidis G Fountzilas T Economopoulos 2008 Carboplatin and paclitaxel in advanced or metastatic endometrial cancer Gynecol Oncol 109 250 254 18299146 10.1016/j.ygyno.2008.01. 028 1:CAS:528:DC%2BD1cXlsFOjsbw%3D
18. R Bartsch C Wenzel G Altorjai U Pluschnig M Rudas RM Mader M Gnant CC Zielinski GG Steger 2007 Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer J Clin Oncol 25 3853 3858 17679724 10.1200/JCO.2007.11. 9776 1:CAS:528:DC%2BD2sXhtFanu7zL (Pubitemid 47477260)
19. Y Ueno T Enomoto Y Otsuki N Sugita R Nakashima K Yoshino C Kuragaki Y Ueda T Aki H Ikegami M Yamazaki K Ito M Nagamatsu T Nishizaki M Asada T Kameda A Wakimoto T Mizutani T Yamada Y Murata 2006 Prognostic significance of p53 mutation in sub optimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin Cancer Lett 241 289 300 16459017 10.1016/j.canlet.2005.10.035 1:CAS:528:DC%2BD28XotV2msb0%3D (Pubitemid 44163043)
20. M Markman J Markman K Webster K Zanotti B Kulp G Peterson J Belinson 2004 Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design J Clin Oncol 22 3120 3125 15284263 10.1200/JCO.2004.05.195 1:CAS:528: DC%2BD2cXpsVGrs74%3D (Pubitemid 41103725)
21. M Harries M Gore 2002 Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease Lancet Oncol 3 537 545 12217791 10.1016/S1470-2045(02)00847-1 1:CAS:528:DC%2BD38Xms1Grsb4%3D (Pubitemid 34993641)
22. G Blackledge F Lawton C Redman K Kelly 1989 Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials Br J Cancer 59 650 653 2713253 10.1038/bjc.1989.132 1:STN:280:DyaL1M3ivV2jsw%3D%3D (Pubitemid 19111764)
23. ME Gore I Fryatt E Wiltshaw T Dawson 1990 Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 207 211 2404837 10.1016/0090-8258(90)90174-J 1:STN:280:DyaK3c7ivVCntw%3D%3D (Pubitemid 20061287)
24. M Markman B Reichman T Hakes W Jones JL Lewis Jr S Rubin L Almadrones W Hoskins 1991 Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin J Clin Oncol 9 1801 1805 1919630 1:STN:280:DyaK38%2FhsVWmsQ%3D%3D